Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ADPT is 22 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell